Non-Hodgkin Lymphoma | Specialty

Rolling Submission of BLA to FDA Completed for Ublituximab/Umbralisib in CLL

March 29th 2021

The rolling submission of a biologics license application to support the approval of ublituximab plus umbralisib as a treatment for patients with chronic lymphocytic leukemia has been completed.

Case Discussion: 68-Year-Old With R/R Follicular Lymphoma

March 29th 2021

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

R/R Follicular Lymphoma: Testing for EZH2

March 29th 2021

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

Evolving Therapies in R/R DLBCL: Concluding Remarks

March 26th 2021

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

March 26th 2021

R/R DLBCL: Novel Therapies in the Pipeline

March 26th 2021

EZH2 Inhibition in R/R FL: Safety & Efficacy Data

March 22nd 2021

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Tazemetostat for R/R Follicular Lymphoma

March 22nd 2021

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

Treating Primary Refractory DLBCL

March 19th 2021

Bridging Therapy in R/R DLBCL

March 19th 2021

Real-World Data Showcase Favorable Outcomes and Less Toxicity With Axi-Cel in Large B-Cell Lymphoma

March 17th 2021

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

R2 Regimen for R/R Follicular Lymphoma

March 15th 2021

An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.

PI3K Inhibitors for R/R Follicular Lymphoma

March 15th 2021

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.

R/R DLBCL: Transplants in the Era of CAR-T

March 12th 2021

CAR T for R/R DLBCL: Improving Access and Utilization

March 12th 2021

Dr. Neelapu on FDA-Approved CAR T-Cell Products Spanning Lymphoma Subtypes

March 9th 2021

Sattva Neelapu, MD, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

D’Angelo Details Combos Designed to Produce Durable Activity in Relapsed/Refractory DLBCL

March 9th 2021

Christopher D'Angelo, MD, discusses emerging CAR T-cell therapies and the challenges with using a 5-drug regimen.

Frontline Ibrutinib Shows Sustained Survival Benefit in TP53-Aberrant CLL

March 8th 2021

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

R/R Follicular Lymphoma: Third-Line Treatment Options

March 8th 2021

Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.

Transplantation for R/R Follicular Lymphoma

March 8th 2021

The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.